# A Pre-market, Two-stages Interventional Clinical Investigation to Evaluate the Safety and the Performance of Fibroin Syrup in Reducing the Gastroesophageal Reflux Disease (GERD) Symptomatology in Nonerosive Reflux Disease (NERD) Patients

> **NCT07563790** · NA · COMPLETED · sponsor: **Rose Pharma SA** · enrollment: 47 (actual)

## Conditions studied

- GERD (Heartburn, Regurgitation, and Dyspepsia)
- Gastroesophageal Reflux (GERD)

## Interventions

- **DEVICE:** Syrup made by hyaluronic acid

## Key facts

- **NCT ID:** NCT07563790
- **Lead sponsor:** Rose Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-24
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-08-08
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07563790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07563790, "A Pre-market, Two-stages Interventional Clinical Investigation to Evaluate the Safety and the Performance of Fibroin Syrup in Reducing the Gastroesophageal Reflux Disease (GERD) Symptomatology in Nonerosive Reflux Disease (NERD) Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07563790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*